{"name":"Immunovant, Inc.","slug":"immunovant","ticker":"IMVT","exchange":"NASDAQ","domain":"immunovant.com","description":"Immunovant, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The company's lead product, IMVT-1401, is a monoclonal antibody targeting the FcRn receptor. Immunovant is positioned to address significant unmet needs in the autoimmune market.","hq":"New York, NY","founded":0,"employees":"","ceo":"Pete Salzmann","sector":"Autoimmune / Immunology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$5.3B","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":101808000,"netIncome":-413840000,"cash":713971000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"IMVT-1401 patent cliff ($0.0B at risk)","drug":"IMVT-1401","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Immunovant Announces FDA Acceptance of BLA for IMVT-1401","summary":"The FDA has accepted the Biologics License Application (BLA) for IMVT-1401, a treatment for primary acquired hypothyroidism.","drugName":"IMVT-1401","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Immunovant Reports Third Quarter 2023 Financial Results","summary":"Immunovant reported its third-quarter 2023 financial results, with a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Immunovant Enters into Agreement with Pfizer to Develop and Commercialize IMVT-1401","summary":"Immunovant has entered into an agreement with Pfizer to develop and commercialize IMVT-1401 in the United States.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOdGVmVUNobi1xWjRyWlNFRVJvaDZKWmFYcVJPT3pWbHU0SXg5a1BVNTU2WklFMU90b3Fhdy1Qa1FmX2thU0JWLUR3ODVqYlp6ZGtDVDV3YUhtUjAyRmZ5VnV2LWxtcUo4Q05ieFB2eU9ZX0NITUdpSkZfMF8zSF9LdEpSR0ZHUmRHRFlyNnFRN1lVZl8tV0daLUtYZTMySWduRF85MEtKdFVwbTh1RzFqcDEzRW9PMk9FSmh3d1FlVlAtUQ?oc=5","date":"2026-04-06","type":"trial","source":"TradingView","summary":"IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints - TradingView","headline":"IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFA0azVGQV9iMG5RODBFcVJZQTJEeUFwbWhaNUU3WnE1YV9vRnl1YUZwa2NUcWkwa3hCU2xtZUtxd01iRGFDVmduT2o5YU1oUUlidW9vWU1QNHlBNlkyamdLd2hNVdIBY0FVX3lxTFA0azVGQV9iMG5RODBFcVJZQTJEeUFwbWhaNUU3WnE1YV9vRnl1YUZwa2NUcWkwa3hCU2xtZUtxd01iRGFDVmduT2o5YU1oUUlidW9vWU1QNHlBNlkyamdLd2hNVQ?oc=5","date":"2026-04-06","type":"trial","source":"Bitget","summary":"IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial - Bitget","headline":"IMVT Shares Drop 2.4% After Batoclimab Fails to Meet Key Goals in Final-Stage Trial","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxNeEdWXy1IUVNLdFBsVDktb3FWQWUxcjBRdGFUMDl2RFhUcWtzem50OEpPbmdMa09hNDZhWm1mOFJfSnRidnFXWXoyUFRrUnVldUVKMUxoWTJDajRNS1kzVmMzMTVJUlhtZXlqaTB4VEJyWXZoUW93R1k0elpHMHhJdGprenhzRTBtelpabE5pQzNOZzhVaHl0cG9NTllXQmdYZWlUVC16Nkx3c09ZT1h0Mk5MNU9ILVRMSGxReXY2Z1h4dWxnNXZ3a3FNTkd1TFdvV1drclNB?oc=5","date":"2026-03-05","type":"pipeline","source":"The Globe and Mail","summary":"Immunovant Stock Surges 17% in 3 Months: What's Driving It? - The Globe and Mail","headline":"Immunovant Stock Surges 17% in 3 Months: What's Driving It?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxQX1JnVDJBTnVHU1doV0hNV2lkWjVYQmlXeGRFQU1JS3REUVFpN3ZRMEF3YjVpN1NoTmlQb19OUVFDZzhkZU9hUVo0b1RxN1ZTa1ItVE05VmVvaHNxdlJyRDUydFVNbk9ROEFiYTJScWJGZ05jWG9FaTZJQ3VHblR3dFdBc1VRVWlzM0k2bzFaYkZ0T1gyNDI0S082MktqSGwtR0dTcUZlQXYzUzNDM3hESGpRZ050Skg5a3NTRDhaTDRWSjMyU3lnS2FXeHBlNFprSkY4NFlUclpPdm9Q0gHiAUFVX3lxTFBTUDROS0NxM09ZRjRXRXBEVG1kWUx3MGJTc19lQ3BRTEJPUTBOTGlwaGo0OHFaVWFISUVOckt5cFh5c2hGd0gwSGJpM044RUtXODZkWEd0Tm5ocjR2a191MkdjaHAzSTlNcXdVenV2R2dpY2w3YVRTbGVjcF9hSWxsUVlLVmlqWi1raXN0OHVvY19PTGFSRzdoRGlyUWk2NEtqUk5kUFZKZ0gxZ0pjMWxUR2hBWEtBQmdtMVV1cjV4S1VCNHNFcVgtc3AwYngtSng1YllVTVVFX1FKNU5lTzlXWXc?oc=5","date":"2026-03-04","type":"trial","source":"simplywall.st","summary":"How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones - simplywall.st","headline":"How Investors Are Reacting To Immunovant (IMVT) Narrower Q3 Loss and 2026 Autoimmune Trial Milestones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeGNEVUpaMWFhMG9jYy01QWFQejVkRkxNa0Z0Z182QVhfWmFuVmZLcTdnbmZvQWZkVGdrbUltZENxRWtKX0o2R19YdVZkOWkzQXlLbXZpU2NCQUtyWjdGQTZvdmw1aDZRSDVDQTlZN183dVBnWEpFaXRYb01qUmlacV9ya0R0NW5wUUgySUVFRkRDUS1oSnpUNUlGSlMyS09JVDhPaWtRUlhFZGw0bVNWeGZMcElyeWNyUTNEMTNaRXI?oc=5","date":"2026-02-17","type":"earnings","source":"TradingView","summary":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - TradingView","headline":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE9DYUYxU1pydFZYR3l2cEV2QUtaOXZrakExYnBhaGJLa1NaYkRKaDJSZVJJRUJMOFp4UTFMa0xOREt6RlpwQU9tcdIBSEFVX3lxTE9DYUYxU1pydFZYR3l2cEV2QUtaOXZrakExYnBhaGJLa1NaYkRKaDJSZVJJRUJMOFp4UTFMa0xOREt6RlpwQU9tcQ?oc=5","date":"2026-02-06","type":"earnings","source":"AlphaStreet","summary":"Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones - AlphaStreet","headline":"Immunovant Inc (IMVT) Shares Surge 12.4% on Q3 Earnings Beat, Pipeline Milestones","sentiment":"positive"},{"date":"2026-02-06","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2026-02-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxPYjhDZ0plTU1kdHVlR3MwcEVIMXNlRlQxLTIxbGNfNmR1bVlFSUVnWjFBTExfaHc5bEdFbW50NGRpMVgwaExOMmxZYXc5N2YxN2xIUk1UcEVUWENmYnJQNnFkQXNtRnU0bTNQNE1KdW93YVFLY1gwSWdXSFNBVTY3VW1qem83RDJzUG9Ba201V05qY2pPajJTS2NXV0JwNThjaWdzb2VvSjNKMmlxNkowSFprNGFheGFK?oc=5","date":"2025-12-12","type":"deal","source":"Seeking Alpha","summary":"Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement - Seeking Alpha","headline":"Immunovant: 'Buy' On Competitive Batoclimab Landscape And IMVT-1402 Advancement","sentiment":"neutral"},{"date":"2025-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNangtYWtkcUhWT2tmRU9JR3ZfUktBX0puOHlLZ21QZkZwdFp1dy1WSmNCdjFldGxMR1FEVWJZRHVqbTcyVjRuUlBwVmFLTGhad0QwRnoxdFZBMXFFWlhHMFU3R0M5TUZ6WV9uOWxXSDl1VzlLX0ZLOENRc2NxcnhzdXFqcTNyUFBBcmlEa3E5Q1Jqc0hfT2VBQWN2eTdlNXpSUU1PQkpIdXdkbldaZ1lCLVRJdjdMMzRpVk9FV1NGSlY?oc=5","date":"2025-12-11","type":"pipeline","source":"TechStock²","summary":"Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus - TechStock²","headline":"Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus - TechStock²","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQX1pEOTJvZzZKa1g5X0kxendaN2lNVHpBZzFmSGpuOWZKS01BVUlrYVViWVV5cGRJZHNUc29hNnFqQWg4REptbno1X054ZlQxUjFZaWZ6X2ROdnJ0TUNsUTNfLXBWV0NWeDZnSXlqNDBLTzFuQjA1MVVvXzNiMTVoWWNJQTVRb3NISF9BUHlDS1dzN3JhTmVITVFUcEhIVUtPaUtjMU1jUHZkTU8wUXpUZTF2c0c5MkdoNWdXMTEwZXBKQXZXRTViZ2dHaDZYbFlTbktOcUlTOFU3QlJvOWh1QVhUT29uZXlreWNOZlZmbXNsOXBlVFdNWFhJY2R6VWoxeEtN?oc=5","date":"2025-12-11","type":"pipeline","source":"Benzinga","summary":"Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On - Benzinga","headline":"Diamond Hill Investment Group, Rhythm Pharmaceuticals, Vail Resorts And Other Big Stocks Moving Higher On","sentiment":"neutral"},{"date":"2025-12-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQalBhRXhrQ3F5allMYWZOV3JyUElEM1Z5Qmc5dWFZenVYdktpcjhxbEJTTFBLY21taWZGTGlySmhpMHF5TWJhTm9fMkllN1pndG0yMGxYanUwOWZTR0tpbDJ2UUYtWkNteXJiTnM1aDlGN25Qem9jcjd1emU5a3I2SFZpd1luNDBU?oc=5","date":"2025-04-23","type":"pipeline","source":"The Pharma Letter","summary":"All change at Immunovant as Pete Salzmann retires - The Pharma Letter","headline":"All change at Immunovant as Pete Salzmann retires","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE4yQzJCSnJac1pXUlZ4UTJBVVhqeVgwR3ZKMGVNOEk1TWxvcDJMUnFIOTFTbmxuRUh1UVh3dVZfRUlNcXFRazBHQUZGdkl2QVp1WXpZ?oc=5","date":"2025-04-21","type":"pipeline","source":"firstwordpharma.com","summary":"Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage - firstwordpharma.com","headline":"Roivant tightens grip on Immunovant as IMVT-1402 takes centre stage","sentiment":"neutral"}],"patents":[{"drugName":"IMVT-1401","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Regeneron Pharmaceuticals","Sanofi"],"therapeuticFocus":["Autoimmune Diseases","Immunology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":101808000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-413840000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":713971000,"cashHistory":[],"totalAssets":776222000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}